Mechanisms of disease: Lineage-specific hematopoietic growth factors

被引：327

作者：

Kaushansky, K ^{[1
]}

机构：

[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, San Diego, CA 92103 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2006年 / 354卷 / 19期

关键词：

D O I：

10.1056/NEJMra052706

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：2034 / 2045

页数：12

共 78 条

[1] A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia [J].

Archimbaud, E ;

Ottmann, OG ;

Yin, JAL ;

Lechner, K ;

Dombret, H ;

Sanz, MA ;

Heil, G ;

Fenaux, P ;

Brugger, W ;

Barge, A ;

O'Brien-Ewen, C ;

Matcham, J ;

Hoelzer, D .

BLOOD, 1999, 94 (11) :3694-3701

[2] c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia [J].

Ballmaier, M ;

Germeshausen, M ;

Schulze, H ;

Cherkaoui, K ;

Lang, S ;

Gaudig, A ;

Krukemeier, S ;

Eilers, M ;

Strauss, G ;

Welte, K .

BLOOD, 2001, 97 (01) :139-146

[3] Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project [J].

Bennett, CL ;

Cournoyer, D ;

Carson, KR ;

Rossert, J ;

Luminari, S ;

Evens, AM ;

Locatelli, F ;

Belknap, SM ;

McKoy, JM ;

Lyons, EA ;

Kim, B ;

Sharma, R ;

Costello, S ;

Toffelmire, EB ;

Wells, GA ;

Messner, HA ;

Yarnold, PR ;

Trifilio, SM ;

Raisch, DW ;

Kuzel, TM ;

Nissenson, A ;

Lim, LC ;

Tallman, MS ;

Casadevall, N .

BLOOD, 2005, 106 (10) :3343-3347

[4] EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer [J].

Bokemeyer, C ;

Aapro, MS ;

Courdi, A ;

Foubert, J ;

Link, H ;

Österborg, A ;

Repetto, L ;

Soubeyran, P .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2201-2216

[5] Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation [J].

Bouscary, D ;

Pene, F ;

Claessens, YE ;

Muller, O ;

Chrétien, S ;

Fontenay-Roupie, M ;

Gisselbrecht, S ;

Mayeux, P ;

Lacombe, C .

BLOOD, 2003, 101 (09) :3436-3443

[6] Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury [J].

Brines, ML ;

Ghezzi, P ;

Keenan, S ;

Agnello, D ;

de Lanerolle, NC ;

Cerami, C ;

Itri, LM ;

Cerami, A .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10526-10531

[7] Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. [J].

Bussel, JB ;

Kuter, DJ ;

George, JN ;

Aledort, LM ;

Lichtin, AE ;

Lyons, RM ;

Nieva, J ;

Wasser, JS ;

Bourgeois, E ;

Kappers-Klunne, M ;

LeFrere, F ;

Schipperus, MR ;

Kelly, R ;

Christal, J ;

Chen, CF ;

Nichol, JL .

BLOOD, 2005, 106 (11) :68A-68A

[8] Granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer - The 40% rule revisited [J].

Calhoun, EA ;

Schumock, GT ;

McKoy, JM ;

Pickard, S ;

Fitzner, KA ;

Heckinger, EA ;

Powell, EF ;

McCaffrey, KR ;

Bennett, CL .

PHARMACOECONOMICS, 2005, 23 (08) :767-775

[9]

CARNOT P, 1906, C R HEBD SEANCES A M, V3, P384

[10] RECOMBINANT-HUMAN-ERYTHROPOIETIN IN THE ANEMIA ASSOCIATED WITH MULTIPLE-MYELOMA OR NON-HODGKINS-LYMPHOMA - DOSE-FINDING AND IDENTIFICATION OF PREDICTORS OF RESPONSE [J].

CAZZOLA, M ;

MESSINGER, D ;

BATTISTEL, V ;

BRON, D ;

CIMINO, R ;

ENLLERZIEGLER, L ;

ESSERS, U ;

GREIL, R ;

GROSSI, A ;

JAGER, G ;

LEMEVEL, A ;

NAJMAN, A ;

SILINGARDI, V ;

SPRIANO, M ;

VANHOOF, A ;

EHMER, B .

BLOOD, 1995, 86 (12) :4446-4453

← 1 2 3 4 5 6 7 8 →